Skip to content

K-Stock Briefing

https://kstockbriefing.com

  • About Us
  • Daily Feed
  • Analyst Insights & IR
  • Disclosures
    • Semiconductors
    • Energy
    • Robotics
    • Bio & Healthcare
  • Toggle search form

[Disclosure] Alteogen (196170) to List 40,820 Additional Common Shares Following Executive Stock Option Exercises

Posted on September 25, 2025July 11, 2026 By K-STOCK Editor No Comments on [Disclosure] Alteogen (196170) to List 40,820 Additional Common Shares Following Executive Stock Option Exercises

Source Fact: Financial Supervisory Service Electronic Disclosure System (DART) / 2025-09-25

Disclosure Type: Additional Listing (Exercise of Stock Options)

💡 3-Second Summary

Alteogen will list an additional 40,820 common shares on September 30, which were newly issued following the exercise of stock options by its executives and employees.

📊 1. [Summary of Core Disclosure Content and Key Figures]

  • Type and Quantity of Additional Shares: 40,820 Common Shares
  • Reason for Additional Listing: Exercise of Stock Options (Stock Purchase Rights)
  • Detailed Breakdown by Tranche (Exercise Date: September 17, 2025):
    • 114th Tranche: 38,000 shares (Exercise Price: KRW 63,889)
    • 115th Tranche: 2,400 shares (Exercise Price: KRW 62,858)
    • 116th Tranche: 420 shares (Exercise Price: KRW 47,417)
  • Par Value per Share: KRW 500
  • Listing Date: September 30, 2025
  • Total Number of Listed Shares After Additional Listing: 53,505,788 Common Shares
  • Dividend Baseline Date: January 1, 2025

📈 2. [Expert Perspective: What This Disclosure Means for Investors]

This disclosure functions as an administrative notification that stock options held by personnel have been exercised, leading to the creation and subsequent listing of new common shares. The exercise of corporate stock options does not stem from immediate changes in operational metrics or core business Fundamental.

The primary metrics for investors to monitor are equity dilution and potential overhang risks. The 40,820 newly added shares constitute only about 0.08% of the enlarged total outstanding share count (53,505,788 shares). Consequently, the dilutive impact on existing shareholder value is likely to be highly limited. However, as the option exercise prices (ranging from KRW 47,417 to KRW 63,889) sit below current market valuations, these shares may be subject to profit-taking sales following the listing date, meaning investors should view this as a minor liquidity tracking point.

📝 Editor’s Comment (by K-STOCK Editor)

Corporate talent is locking in rewards as Alteogen’s growth momentum continues! The upcoming listing involves a total of 40,820 shares, which accounts for a mere 0.08% drop in the bucket compared to Alteogen’s massive base of over 53.5 million outstanding shares. Even if some profit-taking occurs around the September 30 listing date, the volume is light enough to be easily absorbed by standard market liquidity without breaking a sweat. It is best treated as a standard operational milestone celebrating team performance.

📢 Disclaimer and Source Information

Source: This content has been newly structured and written based on the official data submitted to the Financial Supervisory Service Electronic Disclosure System (DART).

Investment Risk Notice: This content is provided solely for information and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest entirely with the investor.

Inquiries: For compliance-related inquiries or copyright requests, please contact ksb220805@gmail.com.

🐂
BULLS
VS
🐻
BEARS

🔥 Bulls vs Bears, drop your analysis in the comments!

Disclosures, Bio & Healthcare

Post navigation

Previous Post: [Disclosure] Alteogen (196170) to List 40,820 Additional Shares Following Exercise of Stock Options
Next Post: [Disclosure] HPSP (403870) to Dispose of KRW 2.63B Worth of Treasury Shares for Employee RSU and Stock Option Payouts

Related Posts

[Disclosure] Alteogen (196170) to Present Bio Platform and Pipeline Roadmaps at ‘Korea Investment Week 2025’ Disclosures
[Disclosure] Alteogen(196170) to Receive KRW 21.9B Milestone Payment from MSD for ‘Keytruda SC’ European Approval Disclosures
[Disclosure] Alteogen(196170) Resolves to Submit Agenda for Conditional KOSDAQ Delisting and KOSPI Transfer to Shareholders’ Meeting Disclosures
[Disclosure] Alteogen (196170) to Participate in Korea Investment Week 2025 Presentation Session Disclosures
[Disclosure] Alteogen (196170) to Hold Overseas IR Hosted by Bank of America, Targeting Global Institutional Investors Disclosures
[Disclosure] Alteogen(196170) Resolves to Convene Extraordinary Shareholders’ Meeting on Dec 8 for KOSPI Transfer Approval Disclosures

Leave a Reply Cancel reply

You must be logged in to post a comment.

  • [Disclosure] Hana Micron (067310) Lifted from Investment Warning Stock Status; Reclassified to Investment Caution on June 9 with Re-designation WarningJuly 8, 2026
  • [Discount Reversal via ADR Listing and Entry into an HBM-Led Super Cycle: SK hynix 000660]July 7, 2026
  • [Discount Narrowing via ADR Listing Momentum and Capital Allocation Diversification: SK Square 402340]July 7, 2026
  • Gaon Cable (000500): Structural Re-rating Driven by North American Infrastructure Expansion and AI Data Center Demand ShocksJuly 7, 2026
  • Hugel (145020): Passing the Trough with Q2 Earnings Surprise and Accelerated U.S. Direct Sales DeploymentJuly 7, 2026

Copyright © 2026 K-Stock Briefing.

Powered by PressBook Grid Dark theme